The effect of hemoperfusion on patients with severe symptoms of covid-19 which are resistant to conventional therapies
Not Applicable
Recruiting
- Conditions
- Hospitalized patients with COVID-19 symptoms.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20180625040232N7
- Lead Sponsor
- Oroumia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Covid-19 patients admitted with severe symptoms who do not respond to conventional therapies based on guidelines
satiscfaction with performing of hemoperfusion
lung involvement more than 50% according to Chest- CT imaging
In patients with lungs involvement less than 50% with respiratory distress, or SO2 less than 88%, despite receiving supplementory oxygen with a reservoir mask or NIV
Exclusion Criteria
uncorrected coagulopathy in patients
vasculitis
sepsis
Patients with low life expectancy due to underlying disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Respiratory status regarding So2. Timepoint: After performing of two session hemoperfusion. Method of measurement: By pulse oximetry.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does hemoperfusion target in severe COVID-19 patients with viral load reduction?
How does hemoperfusion compare to standard-of-care treatments like remdesivir in ICU patients with ARDS from SARS-CoV-2?
Which biomarkers correlate with improved clinical outcomes following hemoperfusion in cytokine storm syndrome associated with U07.1?
What are the potential adverse events associated with hemoperfusion therapy in critically ill patients with viral pneumonia?
Are there combination therapies involving hemoperfusion and antiviral agents showing enhanced efficacy in SARS-CoV-2 treatment?